← Back to Screener
TransCode Therapeutics, Inc. Common Stock (RNAZ)
Price$5.44
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-59.01%
Price vs S&P 500 (4W)-39.33%
VGM Score15.94
Market Capitalization$4.88M
All Metrics
Book Value / Share (Quarterly)$157.61
P/TBV (Annual)1.52x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-23.34
Price vs S&P 500 (YTD)-35.47%
EPS (TTM)$-45.07
10-Day Avg Trading Volume0.01M
EPS Excl Extra (TTM)$-45.07
EPS (Annual)$-50.25
ROI (Annual)-1130.17%
Cash / Share (Quarterly)$14.00
ROA (Last FY)-229.69%
EBITD / Share (TTM)$-48.58
Cash Flow / Share (Annual)$-363.48
P/B Ratio0.03x
P/B Ratio (Quarterly)0.05x
Net Income / Employee (Annual)$-2,888,400
Net Interest Coverage (TTM)-870.99x
ROA (TTM)-48.47%
EPS Incl Extra (Annual)$-50.25
Current Ratio (Annual)2.56x
Quick Ratio (Quarterly)2.81x
3-Month Avg Trading Volume0.15M
52-Week Price Return-25.18%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$32.96
52-Week High$20.99
EPS Excl Extra (Annual)$-50.25
26-Week Price Return-43.08%
Quick Ratio (Annual)2.10x
13-Week Price Return-48.50%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.11x
Enterprise Value$-7.95M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$158.12
3-Month Return Std Dev52.59%
Net Income / Employee (TTM)$-3,363,400
ROE (Last FY)-1130.17%
Net Interest Coverage (Annual)-187.86x
EPS Basic Excl Extra (Annual)$-50.25
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-45.07
ROI (TTM)-53.11%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$4.99
Price vs S&P 500 (52W)-53.39%
Year-to-Date Return-24.74%
5-Day Price Return-17.63%
EPS Normalized (Annual)$-50.25
ROA (5Y Avg)-214.38%
Month-to-Date Return-35.83%
Cash Flow / Share (TTM)$-13.32
EBITD / Share (Annual)$-40.46
LT Debt / Equity (Annual)0.00x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-45.07
P/TBV (Quarterly)0.26x
P/B Ratio (Annual)2.52x
Book Value / Share (Annual)$2.62
Price vs S&P 500 (13W)-58.24%
Beta1.30x
Revenue / Share (TTM)$0.00
ROE (TTM)-53.11%
52-Week Low$5.01
mGradeF
vgmGradeF
Show chart for
Analyst Recommendations
Mar 2025
Apr 2025
May 2025
Jun 2025
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RNAZTransCode Therapeutics, Inc. Common Stock | — | — | F | $5.44 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
TransCode Therapeutics is a biopharmaceutical company developing cancer therapeutics and diagnostics. The company's lead candidate, TTX-MC138, is a nanoparticle-conjugated oligonucleotide in clinical development designed to inhibit metastatic tumor survival. If approved, the therapy aims to achieve durable disease regression and improve long-term patient survival outcomes.